O-025
Oxcarbazepine solution
1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H12N2O2
化学文摘社编号:
分子量:
252.27
NACRES:
NA.24
UNSPSC Code:
41116107
EC Number:
200-835-2
产品名称
Oxcarbazepine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
InChI key
CTRLABGOLIVAIY-UHFFFAOYSA-N
InChI
1S/C15H12N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8H,9H2,(H2,16,19)
SMILES string
NC(=O)N1c2ccccc2CC(=O)c3ccccc13
grade
certified reference material
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in acetonitrile
technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
Quality Level
Gene Information
General description
Oxcarbazepine, marketed under the trade name Trileptal®, is an anticonvulsant developed and prescribed for treatment of epilepsy. In recent years, Oxcarbazepine has shown efficacy in treatment of mood disorders. This certified solution standard is suitable as starting material for the preparation of calibrators and controls in oxcarbazepine testing by GC/MS or LC-MS/MS.
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Trileptal is a registered trademark of Novartis Corporation
signalword
Danger
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2
存储类别
3 - Flammable liquids
wgk
WGK 2
flash_point_f
35.6 °F - closed cup
flash_point_c
2 °C - closed cup
法规信息
危险化学品
此项目有
Gaetano Zaccara et al.
Seizure, 22(7), 528-536 (2013-04-30)
Analysis of overall tolerability and neurological adverse effects (AEs) of eslicarbazepine acetate (ESL), lacosamide (LCM) and oxcarbazepine (OXC) from double-blind, placebo-controlled trials. Indirect comparisons of patients withdrawing because of AEs, and the incidence of some vestibulocerebellar AEs between these three
Humberto Saconato et al.
Sao Paulo medical journal = Revista paulista de medicina, 127(3), 150-159 (2009-10-13)
It has been estimated that 50 million people worldwide suffer from epilepsy and around 30% will not achieve adequate control over the disease. The aim was to evaluate the effectiveness of oxcarbazepine for refractory partial or generalized epilepsy. Systematic review.
James F Knudsen et al.
Pediatric neurology, 37(2), 134-137 (2007-08-07)
Oxcarbazepine, a carbamazepine analog, was approved for use as an antiepileptic agent in the United States in 2000. A search of the United States Food and Drug Administration's Adverse Event Reporting System identified nine cases of oxcarbazepine-associated angioedema in pediatric
[The use of oxcarbazepine (trileptal) in young epileptic women].
P N Vlasov et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 109(6), 72-75 (2009-08-19)
Ekaterine Popova et al.
Expert review of neurotherapeutics, 7(6), 617-626 (2007-06-15)
Oxcarbazepine is an antiepileptic drug that has been approved by the US FDA and is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and children aged over 4 years. The aim of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持